Market
Objective response rate for Eli Lilly's PI3Kα inhibitor in trials by end of 2025?
2
Resolution / Starting Odds
Below 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Above 40% • 25%
Clinical trial results published by Eli Lilly
Story
Eli Lilly to Acquire Scorpion's PI3Kα Cancer Drug for Up to $2.5 Billion Including $1 Billion Upfront
Jan 13, 2025, 02:41 PM
Eli Lilly and Company has announced an agreement to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program targeting advanced solid tumors, including breast cancer. The deal is worth up to $2.5 billion, comprising a $1 billion upfront payment and up to $1.5 billion in performance-based milestones. The PI3Kα inhibitor is currently in Phase 1/2 clinical trials, being evaluated as monotherapy or in combination therapies, with preliminary data showing an objective response rate of 23%. Lilly's Chief Scientific Officer, Dan Skovronsky, commented that the acquisition "checked all the boxes" for the company's strategic objectives, as it aims to expand its oncology pipeline with innovative clinical programs.
View original story
Similar markets
20% to 40% • 25%
More than 60% • 25%
Less than 20% • 25%
40% to 60% • 25%
More than 15% • 25%
5% to 10% • 25%
Less than 5% • 25%
10% to 15% • 25%
Less than 10% • 25%
More than 30% • 25%
20-30% • 25%
10-20% • 25%
Fewer than 30 countries • 25%
30 to 60 countries • 25%
60 to 90 countries • 25%
More than 90 countries • 25%
More than 80% • 25%
Less than 50% • 25%
50% to 74% • 25%
75% to 80% • 25%
Three or more • 25%
Two • 25%
None • 25%
One • 25%
Yes • 50%
No • 50%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
20% to 30% • 25%
10% to 20% • 25%
More than 30% • 25%
Less than 10% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%